Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands

被引:13
|
作者
Freudenburg-de Graaf, W. [1 ,2 ]
Knol, M. J. [3 ]
van der Ende, A. [1 ,2 ]
机构
[1] Univ Amsterdam, Dept Med Microbiol & Infect Prevent, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands
[3] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control Netherlands, Bilthoven, Netherlands
基金
英国惠康基金;
关键词
Neisseria meningitidis; 4CMenB vaccine; Whole-genome sequencing; gMATS; B VACCINE; BACTERICIDAL ANTIBODIES; PERSISTENCE; AGE; IMMUNOGENICITY; IMMUNIZATION; ADOLESCENTS; INFANTS; STRAIN;
D O I
10.1016/j.vaccine.2020.10.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited. Recently, genomic MATS (Meningococcal Antigen Typing System) was developed as a tool to predict strain coverage, using vaccine antigens sequence data. We characterized all invasive meningococcal isolates received by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in two epidemiological years 2017-2019 using whole-genome sequencing and determined serogroup, clonal complex (cc) and estimated 4CMenB vaccine coverage by gMATS. Of 396 cases of invasive meningococcal disease, corresponding to an incidence of 1.22 cases/10(5) inhabitants, 180 (45%) were serogroup W, 155 (39%) serogroup B, 46 (12%) serogroup Y, 10 (3%) serogroup C, 2 non-groupable (0.5%) and 3 (0.7%) unknown. The incidence was the highest among 0-4 years olds (4 cases/10(5) inhabitants), and 57/72 (79%) of these cases were serogroup B. Serogroup W predominated among persons 45 years of age or older with 110/187 (59%) cases. Serogroup B isolates comprised 11 different clonal complexes, with 103/122 (84%) isolates belonging to 4 clonal complexes: cc32, cc41/44, cc269 and cc213. In contrast, serogroup W isolates were genetically similar with 95% belonging to ccl 1. Of 122 serogroup B isolates, 89 (73%; 95% CI: 64-80%) were estimated to be covered by 4CMenB and the degree of coverage varied largely by clonal complex and age. Among the 0-4 year olds, 25 of 43 (58%; 95% CI: 43-72%) MenB isolates were estimated to be covered. Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:7850 / 7857
页数:8
相关论文
共 50 条
  • [41] Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules
    Biolchi, Alessia
    Tomei, Sara
    Santini, Laura
    Welsch, Jo Anne
    Toneatto, Daniela
    Gaitatzis, Nikolaos
    Bai, Xilian
    Borrow, Ray
    Giuliani, Marzia Monica
    Mori, Elena
    Pizza, Mariagrazia
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 725 - 731
  • [42] 4CMenB vaccine effectiveness: reasons for optimism
    Basta, Nicole E.
    Christensen, Hannah
    LANCET, 2016, 388 (10061): : 2719 - 2721
  • [43] Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study
    Wang, Bing
    Giles, Lynne
    Andraweera, Prabha
    McMillan, Mark
    Almond, Sara
    Beazley, Rebecca
    Mitchell, Janine
    Lally, Noel
    Ahoure, Michele
    Denehy, Emma
    Koehler, Ann
    Flood, Louise
    Marshall, Helen
    LANCET INFECTIOUS DISEASES, 2022, 22 (07): : 1011 - 1020
  • [44] Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae
    Hadad, Ronza
    Jacobsson, Susanne
    Pizza, Mariagrazia
    Rappuoli, Rino
    Fredlund, Hans
    Olcen, Per
    Unemo, Magnus
    APMIS, 2012, 120 (09) : 750 - 760
  • [45] Use of a multicomponent, recombinant, meningococcal serogroup B vaccine ( 4CMenB) for bacterial meningitis prevention
    Esposito, Susanna
    Castellazzi, Luca
    Bosco, Annalisa
    Musio, Alessandra
    Stoddard, Jeffrey
    IMMUNOTHERAPY, 2014, 6 (04) : 395 - 408
  • [46] Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study
    Parikh, Sydel R.
    Andrews, Nick J.
    Beebeejaun, Kazim
    Campbell, Helen
    Ribeiro, Sonia
    Ward, Charlotte
    White, Joanne M.
    Borrow, Ray
    Ramsay, Mary E.
    Ladhani, Shamez N.
    LANCET, 2016, 388 (10061): : 2775 - 2782
  • [47] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    Miguel O’Ryan
    Jeffrey Stoddard
    Daniela Toneatto
    James Wassil
    Peter M. Dull
    Drugs, 2014, 74 : 15 - 30
  • [48] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    O'Ryan, Miguel
    Stoddard, Jeffrey
    Toneatto, Daniela
    Wassil, James
    Dull, Peter M.
    DRUGS, 2014, 74 (01) : 15 - 30
  • [49] Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations
    Fernandez-Prada, Maria
    Martinez-Ortega, Carmen
    Hidalgo-Pena, Lara
    Alvarez-Vazquez, Clara
    Aguirre-Del Pino, Rodrigo
    Huerta-Gonzalez, Ismael
    FARMACIA HOSPITALARIA, 2018, 42 (05) : 191 - 196
  • [50] Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients
    Robin, Christine
    Redjoul, Rabah
    Terrade, Aude
    Deghmane, Ala-Eddine
    Cabanne, Ludovic
    Cordonnier, Catherine
    Taha, Muhamed-Kheir
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (12) : 1609 - 1614